Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 2 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
Blood Adv. 2024 Feb 13;8(3):629-639. doi: 10.1182/bloodadvances.2023011219.
Blood Adv. 2024.
PMID: 38029373
Free PMC article.
Review.
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Teichman J, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring JM, Nevill TJ, Delage R, Elemary M, Banerji V, Houston B, Mozessohn L, Chodirker L, Zhang L, Siddiqui M, Parmentier A, Leitch HA, Buckstein RJ.
Teichman J, et al.
Haematologica. 2023 Feb 1;108(2):532-542. doi: 10.3324/haematol.2022.280723.
Haematologica. 2023.
PMID: 35979720
Free PMC article.
Survival was evaluated by TSAT and ferritin (<50%, 50-80%, >80%), (500 mug/L, 501-800 mug/L, >800 mug/L). In 718 patients, median age was 74 years; 12%, 31%, 29%, 15% and 13% were IPSS-R very low, low, intermediate, high and very high. ...By multivar …
Survival was evaluated by TSAT and ferritin (<50%, 50-80%, >80%), (500 mug/L, 501-800 mug/L, >800 mug/L). In 7 …
Item in Clipboard
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D.
Buckstein R, et al.
Leuk Lymphoma. 2022 Dec;63(13):3165-3174. doi: 10.1080/10428194.2022.2109154. Epub 2022 Sep 12.
Leuk Lymphoma. 2022.
PMID: 36095125
Item in Clipboard
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Amitai I, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Chodirker L, Mozessohn L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R.
Amitai I, et al.
Br J Haematol. 2021 Jul;194(2):319-324. doi: 10.1111/bjh.17537. Epub 2021 May 31.
Br J Haematol. 2021.
PMID: 34060069
Item in Clipboard
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, Zhang L, Mamedov A, Stanworth SJ, Lin Y.
Buckstein R, et al.
Transfusion. 2024 Feb;64(2):223-235. doi: 10.1111/trf.17721. Epub 2024 Feb 7.
Transfusion. 2024.
PMID: 38323704
Clinical Trial.
STUDY DESIGN AND METHODS: We conducted a pilot randomized multi-center study of two transfusion algorithms (liberal, to maintain Hb 110-120 g/L, transfuse 2 units if Hb < 105 g/L and 1 unit if Hb 105-110 g/L vs. restrictive, 85-105 g/L, transfuse 2
…
STUDY DESIGN AND METHODS: We conducted a pilot randomized multi-center study of two transfusion algorithms (liberal, to maintain Hb 110-120 …
Item in Clipboard
Cite
Cite